|
 |
| home > epc > winter 2001 > arm for the pharmaceutical industry - protecting pharmaceutical brands and the impact of the internet |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Intellectual property has always been vital to the pharmaceutical industry. The future earnings of new drugs are assessed on the basis that they will have very high profit margins because of their virtual monopoly on the market until the patent expires. But once the 20-year patent expires, pharmaceutical companies increasingly rely on their brands to sustain sales on their blockbusting drugs.
The growth of the Internet is further complicating this issue. Whilst it offers opportunities to develop brands in new ways online, it also harbours many dangers for companies, particularly in controversial industries such as pharmaceuticals.
Pharmaceutical companies have long held the view that patents equal profits. Their products require vast investment in research and development, as well as extensive and rigorous testing, before they reach the market. But, given the fact that once a drug is approved, a well-drafted patent gives a pharmaceutical company 20 years of uninterrupted monopoly in which to sell and market a drug, pharmaceutical giants have traditionally paid more attention to their patent portfolio than to their trade marks and brands. GlaxoSmithKline's ranitidine hydrochloride (Zantac) is a good case in point. Zantac is an anti-ulcer drug for which Glaxo obtained a patent. To get an idea of the potential value of the patent, this monopoly was worth approximately two to three million pounds in profits to Glaxo for every single day that it lasted.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PAT and Quality by Design for Biopharmaceuticals
25-26 May 2010, London, UK
Pharma IQ is delighted to announce the inaugural PAT and quality by design for biopharmaceuticals, being held in London on the 25th-26th May 2010. With PAT and quality by design techniques now established within the small molecules field the focus is shifting to application within the biopharmaceuticals arena, with key regulatory bodies such as the FDA and EMEA actively getting involved I pilot case studies. This event will bring together professionals specifically tasked with implementing PAT and QbD tools and techniques specifically within the bioprocess and bioproduction area.
More info >> |
|
 |
News and Press Releases |
 |
DB Schenker receives Accreditation as Qualified Envirotainer Provider in Europe and Asia High-quality solutions for integrated cold chain offered
DB Schenker has gained Accreditation as a Qualified Envirotainer Provider (QEP) at several stations in Europe and Asia by EnvirotainerAB, the Sweden-based provider of active temperature-controlled air cargo containers. The accreditation, which verifies that DB Schenker can manage temperature sensitive shipments that are shipped in Envirotainer containers in accordance with Good Distribution Practice, has been awarded for the European stations in Brussels, Basel, Frankfurt, Geneva, Mannheim, Stuttgart, Vienna and Zurich as well as the Singapore operation.
More info >> |
|
 |
